Source: Annual Congress 2006 - Lung cancer biology and chemosensitivity
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Morishita, H. Katoh, Y. Oki, R. Kamazawa, S. Sato, M. Suzuki, M. Nishio, K. Yoshikawa, T. Niimi, H. Maeda, H. Kobayashi (Nagoya, Seto, Osaka, Japan). Clinical usefulness of the novel drug sensitivity test for malignancy using pleural effusion. Eur Respir J 2006; 28: Suppl. 50, 2015

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011 A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions Source: Eur Respir J 2013; 41: 18-24 Year: 2013 Diagnostic utility of cell block method combined with conventional smear cytology in the diagnosis of exudative pleural effusions accompanying lung cancer Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control? Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 The role of diagnostic thoracoscopy in patients with lung cancer and pleural effusion Source: Eur Respir J 2003; 22: Suppl. 45, 542s Year: 2003 Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 754s Year: 2007 Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Source: Eur Respir J 2011; 37: 162-168 Year: 2011 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Diagnostic value of pleural effusion for the detection of EGFR in NSCLC: a meta-analysis Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019 Epidemiology and clinical problems of orphant pleural adenocarcinoma Source: Annual Congress 2006 - Medical and surgical management of malignant pleuritis Year: 2006 Pleural effusion in lung cancer and targeted therapy Source: Hands-on Course 2013 - Medical Thoracoscopy Year: 2013 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Survival of lung adenocarcinoma patients with malignant pleural effusion Source: Eur Respir J 2013; 41: 1409-1418 Year: 2013 Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Evaluation of chemotherapy response determined by volumetric method in malignant pleural mesothelioma and its effect on determination to survival Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003